Michael R Mcdevitt

List of Publications by Year
in descending order

Version: 2024-02-01

39 papers	3,112 citations	279798 23 h-index	302126 39 g-index
42 all docs	42 docs citations	42 times ranked	3958 citing authors

#	Article	IF	Citations
1	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	6.4	4
2	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical Cancer Research, 2021, 27, 532-541.	7.0	19
3	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	7.0	13
4	Fibrillar pharmacology of functionalized nanocellulose. Scientific Reports, 2021, 11, 157.	3.3	8
5	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	3.6	6
6	Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics, 2020, 10, 11359-11375.	10.0	26
7	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted Î±-particle therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15172-15181.	7.1	16
8	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with Î± Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 459-473.	1.0	13
9	Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled Î±-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles. Biomaterials, 2020, 241, 119858.	11.4	35
10	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research, 2019, 25, 881-891.	7.0	21
11	Î±-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studiesâ€"Part 2. Journal of Nuclear Medicine, 2018, 59, 1020-1027.	5.0	72
12	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629.	12.8	37
13	Targeted and Nontargeted Î±-Particle Therapies. Annual Review of Biomedical Engineering, 2018, 20, 73-93.	12.3	46
14	Î±-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studiesâ€"Part 1. Journal of Nuclear Medicine, 2018, 59, 878-884.	5.0	131
15	The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota. International Journal of Nanomedicine, 2018, Volume 13, 5275-5286.	6.7	2
16	Advances in the clinical translation of nanotechnology. Current Opinion in Biotechnology, 2017, 46, 66-73.	6.6	30
17	Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS ONE, 2017, 12, e0183902.	2.5	18
18	In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget, 2017, 8, 65917-65931.	1.8	17

#	Article	IF	Citations
19	Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma. Journal of Nuclear Medicine, 2016, 57, 1576-1582.	5.0	30
20	Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine, 2016, 8, 331ra39.	12.4	88
21	Deconvoluting hepatic processing of carbon nanotubes. Nature Communications, 2016, 7, 12343.	12.8	42
22	Remodeling the Vascular Microenvironment of Glioblastoma with Î±-Particles. Journal of Nuclear Medicine, 2016, 57, 1771-1777.	5.0	25
23	Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes. International Journal of Nanomedicine, 2014, 9, 4245.	6.7	21
24	Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with ²²⁵Ac for Î±-Particle Radioimmunotherapy of Cancer. Journal of Nuclear Medicine, 2014, 55, 1492-1498.	5.0	73
25	Dialytic Separation of Bundled, Functionalized Carbon Nanotubes from Carbonaceous Impurities. Crystals, 2014, 4, 450-465.	2.2	1
26	Fibrillous Carbon Nanotube: An Unexpected Journey. Critical Reviews in Oncogenesis, 2014, 19, 261-268.	0.4	7
27	Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nature Nanotechnology, 2013, 8, 763-771.	31.5	99
28	Deploying RNA and DNA with Functionalized Carbon Nanotubes. Journal of Physical Chemistry C, 2013, 117, 5982-5992.	3.1	35
29	Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International Journal of Nanomedicine, 2010, 5, 783.	6.7	117
30	Paradoxical glomerular filtration of carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12369-12374.	7.1	372
31	Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews Clinical Oncology, 2010, 7, 266-276.	27.6	173
32	Synthesis and Biodistribution of Oligonucleotide-Functionalized, Tumor-Targetable Carbon Nanotubes. Nano Letters, 2008, 8, 4221-4228.	9.1	81
33	Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes. Journal of Nuclear Medicine, 2007, 48, 1180-1189.	5.0	414
34	PET Imaging of Soluble Yttrium-86-Labeled Carbon Nanotubes in Mice. PLoS ONE, 2007, 2, e907.	2.5	169
35	Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 1790-1790.	1.4	12
36	Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. Journal of Nuclear Medicine, 2004, 45, 129-37.	5.0	79

#	Article	IF	Citations
37	Targeted Î± particle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-1239.	1.4	430
38	Design and synthesis of 225Ac radioimmunopharmaceuticals. Applied Radiation and Isotopes, 2002, 57, 841-847.	1.5	187
39	Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-9.	1.4	143